A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year ...

Corey J. Langer, MD, FACP Disclosures February 08, 2001 0 Question A 56-year-old man with small-cell lung cancer (SCLC) has a solitary brain metastasis on MRI with gadolinium.

Between 2018 and 2023, 100 patients with small cell lung cancer and 1-10 brain metastases were enrolled in this single arm, multi-center, phase 2 trial of stereotactic treatment.

In 2015, results from gave difficult-to-treat small-cell lung cancer (SCLC) a much-needed boost. The study by Ben Slotman, MD, PhD, chairman of the Department of Radiation Oncology at VU ...

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve survival in a randomized trial. As compared with CRT alone, concurrent ...

Primary Source Journal of Clinical Oncology Source Reference: Bogart JA, et al "Radiation and systemic therapy for limited-stage small-cell lung cancer" J Clin Oncol 2022; 40; 6: 661-670.

2. Three Fractionated SRS Treatments Versus One MSK is a participating institution in a large, phase 3 trial testing fractionated SRS versus standard SRS in patients with intact brain metastases ...

The initial treatment was 55.5% chemotherapy and radiation, 20.5% chemotherapy alone, 3.5% radiation therapy alone, 20% neither chemotherapy nor radiation therapy, and 0.5% not reported.

NRG-LU005 randomly assigned patients with limited-stage SCLC to receive chemotherapy (etoposide with cisplatin or carboplatin) and radiation for up to 7 weeks with or without atezolizumab for up ...

In a phase 2 trial, Mass General Brigham researchers found patients were successfully treated with targeted radiation rather than the historical standard of whole brain radiation. A new study led by ...